Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.

MLA

Kang, Eun Young, et al. “Refined Cut-off for TP53 Immunohistochemistry Improves Prediction of TP53 Mutation Status in Ovarian Mucinous Tumors: Implications for Outcome Analyses.” Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc, vol. 34, no. 1, Jan. 2021, pp. 194–206. EBSCOhost, https://doi.org/10.1038/s41379-020-0618-9.

APA

Kang, E. Y., Cheasley, D., LePage, C., Wakefield, M. J., da Cunha Torres, M., Rowley, S., Salazar, C., Xing, Z., Allan, P., Bowtell, D. D. L., Mes-Masson, A.-M., Provencher, D. M., Rahimi, K., Kelemen, L. E., Fasching, P. A., Doherty, J. A., Goodman, M. T., Goode, E. L., Deen, S., … Gorringe, K. L. (2021). Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc, 34(1), 194–206. https://doi.org/10.1038/s41379-020-0618-9

Chicago

Kang, Eun Young, Dane Cheasley, Cecile LePage, Matthew J Wakefield, Michelle da Cunha Torres, Simone Rowley, Carolina Salazar, et al. 2021. “Refined Cut-off for TP53 Immunohistochemistry Improves Prediction of TP53 Mutation Status in Ovarian Mucinous Tumors: Implications for Outcome Analyses.” Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc 34 (1): 194–206. doi:10.1038/s41379-020-0618-9.